Obagi Medical has announced significant clinical findings regarding its hyaluronic acid injectables at the American Society for Dermatologic Surgery (ASDS) Annual Meeting, held from November 13 to 16, 2025, in Chicago, Illinois. The company, known for its innovative physician-dispensed skincare solutions and a subsidiary of Waldencast plc (NASDAQ: WALD), highlighted data from a pivotal FDA study comparing two hyaluronic acid fillers used for midface augmentation.
The study’s results showed a marked improvement in the appearance of nasolabial folds, which are the lines that extend from the sides of the nose to the corners of the mouth. This data was presented by Dr. Sue Ellen Cox, and the abstract earned recognition as one of the top ten presented at the conference.
Key Findings on Hyaluronic Acid Fillers
The clinical data emphasized the efficacy of Obagi’s hyaluronic acid injectables in enhancing facial aesthetics. In the FDA study, participants reported significant satisfaction levels regarding the treatment’s outcomes. The findings suggest that Obagi’s products not only improve facial volume but also contribute to a more youthful appearance by reducing the visibility of nasolabial folds.
Dr. Cox noted that the study’s strength lies in its comprehensive approach to evaluating patient outcomes. “Our findings reflect the promising potential of hyaluronic acid fillers in aesthetic dermatology,” she stated. The positive feedback from both practitioners and patients indicates a growing acceptance of these injectables in the cosmetic industry.
Industry Impact and Future Directions
Obagi Medical’s presentation at the ASDS Annual Meeting positions the company as a key player in the rapidly evolving field of aesthetic treatments. With the increasing demand for non-surgical cosmetic solutions, the data shared could significantly influence physician prescribing behaviors and patient choices.
As the aesthetic market expands, Obagi plans to continue its research and development efforts, focusing on enhancing the effectiveness and safety of its injectables. The company aims to leverage the insights gained from this study to further refine its product offerings, addressing the needs of both practitioners and patients.
The recognition of Obagi’s abstract at the ASDS meeting underscores the importance of clinical research in shaping the future of skincare and aesthetic solutions. As consumer interest in these treatments grows, Obagi Medical remains committed to innovation, ensuring that its products meet the highest standards of efficacy and safety.
